Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains the importance of checkpoint inhibitors, specifically avelumab, in merkel cell cancers. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.